As weight loss drugs have risen all around the world, it has reshaped users’ relationships for better and for worseAs GLP-1 use continues to rise in the US and the UK, people’s bodies are being reshaped – as are their relationships.“Relationships tend to develop a sense of equilibrium and predictability over time,” says Dr Lindsey Berisha, a licensed clinical psychologist who has worked with clients using GLP-1s for over 10 years. “When one partner undergoes a significant change, it can shift that equilibrium, and even positive change can create uncertainty for both partners.” Continue reading…

Thursday, September 10 – Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.

Thursday, September 10 – Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.

Thursday, September 10 – A CDC Covid restructuring, public trust in Fauci, and more health news from Morning Rounds

Thursday, September 10 – (MedPage Today) — Growing evidence linked GLP-1 drugs to a reduced risk of exacerbations of two types of chronic airways disease: asthma and chronic obstructive pulmonary disease (COPD).
Based on real-world records from the U.K., affected patients…

Thursday, September 10 – (MedPage Today) — Men predisposed to androgenetic alopecia had a higher risk of hair loss when using GLP-1 drugs, a Mendelian randomization study suggested. (Journal of Investigative Dermatology)
Truveta data indicated a 19% increase in GLP-1…

Thursday, September 10 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.

Wednesday, September 9 – Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.

Wednesday, September 9 – Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.

Wednesday, September 9 – The diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40%, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.

Sunday, September 6 – A new review found that GLP-1s offer significant improvements in obstructive sleep apnea associated with obesity. vitapix/E+/Getty Images

New research has found that GLP-1 drugs may improve obstructive sleep apnea (OSA) related to obesity.

The effects of tirzepatide (Zepound), which is FDA approved for OSA, were especially notable.

GLP-1s appear to improve OSA associated with obesity by promoting fat loss in the neck, throat, and tongue.

CPAP therapy should be continued until a physician has confirmed remission with a sleep study.

Sunday, September 6 – (MedPage Today) — GLP-1 receptor agonists may be powerful tools for treating obesity and cardiometabolic disease, but relying on medications alone risks overlooking the forces helping drive the obesity epidemic, according to Laura Schmidt, PhD…

Sunday, September 6 – Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide (GZR-18), granting Menarini Group rights across 39 European countries in a deal worth up to €726 million (US$844 million). Bofanglutide is a biweekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently discovered and developed by Beijing-based Gan & Lee.

Saturday, September 5 – (MedPage Today) — Prescribing GLP-1 receptor agonists to children ages 8 to 11 years with obesity surged 310-fold since 2019, despite a lack of FDA approval in kids under 12, a large cross-sectional analysis showed.
Among over 3.5 million children…

Saturday, September 5 – Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first prescribed, a new study shows.

Saturday, September 5 – (MedPage Today) — Adults with serious mental illness (SMI) received GLP-1 drug prescriptions at higher rates than those without SMI from 2018 to 2024, an analysis of U.S. insurance claims data showed.
Among people with an underlying GLP-1-indicating…

Saturday, September 5 – Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbott, Abbvie, Alvotech, Astrazeneca, Beyond, Biogen, Biontech, Bonesupport, Cortec, Cytomx, Daiichi Sankyo, Eisai, Eli Lilly, GE, Gilead, Hamamatsu, Highlife, Hutchmed, Juniper, Karyopharm, Kowa, Moderna, Nicox, Novavax, Palvella, Pfizer, Pharmassentia, Pixcell, Priovant, Revolution, Roche, Ropca, Scholar Rock, SL, Takeda, T-Maximum, Uniqure, United, Vara, Viiv, Xentria, Zambon.

Thursday, September 3 – The FDA has approved Mounjaro for cardiovascular risk reduction in people with type 2 diabetes. Milko · E+/Getty

The FDA has approved Mounjaro to help reduce the risk of major cardiovascular events in people with type 2 diabetes who are at high risk.

A major clinical trial found that Mounjaro performed as well as Trulicity for reducing the risk of heart attack, stroke, and cardiovascular death.

Thursday, September 3 – Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on understanding disease biology and selecting the right drug candidates to derisk clinical trials.

Wednesday, September 2 – “He’s on the highest dose, and he likes to outrun the feeling that…Ozempic gives you to stop eating.”View Entire Post ›

Wednesday, September 2 – (MedPage Today) — Medical liability cases involving GLP-1 receptor agonist use in dermatology have occurred infrequently to date but warrant careful attention as the use increases, a medicolegal review suggests.
A review of the LexisNexis legal…

Wednesday, September 2 – (MedPage Today) — The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, Eli Lilly announced.
Global type 1 diabetes prevalence…

Wednesday, September 2 – An updated systematic review evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and coagonists among adults with overweight or obesity without diabetes found that, among currently available treatments, tirzepatide produced the greatest weight loss, while newer experimental drugs showed even larger effects.

Tuesday, September 1 – There is no link between the widely used diabetes and obesity medications known as GLP-1 receptor agonists and increased suicidal thoughts, depression or other serious psychiatric harm, based on an integrative review of current scientific evidence conducted by researchers at New Mexico State University and the University of Nevada, Las Vegas.

Tuesday, September 1 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with increased cumulative gallbladder and biliary events in youths, according to a retrospective analysis of TriNetX data.
Among over 37,000 adolescents and young adults with overweight…

Tuesday, September 1 – (MedPage Today) — Recent studies suggest that people with type 2 diabetes on GLP-1 receptor agonists were less likely to develop tuberculosis (TB) or be hospitalized or die from infections.
In an international study of more than 7 million people…

Tuesday, September 1 – Since the Federal Food, Drug and Cosmetics Act requires the U.S. FDA to maintain an updated list of prescription drugs that are in shortage, does the FDA have to go through months of a notice-and-comment rulemaking before it can remove a drug from the list when the agency determines it’s no longer in short supply? The U.S. Court of Appeals for the Fifth Circuit danced around that question even as it upheld a lower court’s summary judgment shutting down compounders’ challenges to the FDA removing Eli Lilly and Co.’s and Novo Nordisk A/S’ popular GLP-1 drugs from the shortage list in October 2024.

Tuesday, September 1 – Another hospital system sues CVS Health, how Medicaid cuts will change everything, and more

Sunday, August 30 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.

Saturday, August 29 – (MedPage Today) — Nearly half of adults who started semaglutide (Wegovy) for obesity management stopped treatment within a year, a Danish cohort study showed.
Among 157,822 first-time semaglutide initiators without diabetes, 49% discontinued…

Saturday, August 29 – With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.

Saturday, August 29 – The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.

Saturday, August 29 – Kentucky has one of the highest childhood obesity rates in the country, and the health consequences carry forward throughout life. That’s one of the reasons researchers at the University of Kentucky are leading a groundbreaking clinical trial to determine whether medical intervention can reverse the early signs of heart disease in children struggling with severe obesity.

Thursday, August 27 – Can GLP-1s really help treate PMOS (Polyendocrine Metabolic Ovarian Syndrome)? Experts answer 3 key questions.

Saturday, August 29 – (MedPage Today) — Starting a GLP-1 receptor agonist was associated with significantly lower risks of death and cardiovascular events in adults with serious mental illness (SMI), a target trial emulation showed.
Among 195,184 propensity score…

Saturday, August 29 – (MedPage Today) — The use of GLP-1 receptor agonists was linked to improved remission rates in patients with ulcerative colitis, a retrospective cohort study suggested.
Among 300 patients with ulcerative colitis, use of liraglutide (Victoza…

Saturday, August 29 – About 1 in 5 American adults have taken a GLP-1 medication, and most of them, including those with health insurance, say the drugs are difficult to afford. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, which is why the Medicare GLP-1 Bridge program made a big splash when it launched in July.

Saturday, August 29 – (MedPage Today) — Note that some links may require registration or subscription.
Country music superstar Dolly Parton, 80, died Tuesday after a brief battle with an undisclosed type of cancer, according to her family. She had also been dealing…